You need to be logged in to view this video
The CIA, CRISPR, and Cholesterol: The Latest Developments in Biotech
Released on Thursday, November 10, 2022•ETFs
CRISPR technology has had two watershed moments this summer, indicating that it is about change healthcare as we know it. Since then, there have been investments into CRISPR companies from the CIA and developments in the heart disease space. Learn about the upcoming catalysts for publicly traded gene-editing companies. At its core, CRISPR is a pair of biological scissors that cuts and replaces genes in living organisms' cells.
Kevin Kelly is responsible for product design, structuring, managing retail and institutional investment research, and capital markets. He also serves as the CEO of Kelly Benchmark Indexes, the index provider, and sponsor of the SRVR and INDS ETFs. In September 2014, Nasdaq named Mr. Kelly an ETF Insider, and he is a recognized leader in ETF design, distribution and growth with his extensive track record of launching multi-billion-dollar ETFs. Mr. Kelly's thought leadership on markets, derivatives, e-commerce, and technology can be found weekly in top media outlets.
Filter By Category
Filter By Keywords